StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Goldman Sachs Remains Bullish on BioMarin Pharma (BMRN) Following 1Q
April 26, 2018 8:12 AM
Goldman Sachs reiterated a Buy rating and $132.00 price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) following the company's 1Q ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst EPS View
Next Articles
BioMarin Pharma (BMRN) Misses Q1 EPS by 8c
April 25, 2018 4:06 PM
BioMarin Announces First Quarter 2018 Financial Results
April 25, 2018 4:05 PM
BioMarin Pharma (BMRN) Says NEJM Published Open-label Study Showing Brineura Reduced Rate of Clinical Decline of Children with CLN2 Disease
April 24, 2018 2:32 PM
New England Journal of Medicine Published Open-label Study Showing Brineura® (cerliponase alfa) Reduced the Rate of Clinical Decline of Children with CLN2 Disease, a Form of Batten Disease
April 24, 2018 2:30 PM
